Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zubsolv Induction for Opioid Dependence
NCT01848054Phase 3Completed
- Sponsor
- Orexo AB
- Start
- Jun 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of buprenorphine + naloxone in opioid use disorder (OUD) (2 arms), sponsored by Orexo AB. Primary endpoint: Retention in Treatment at Day 3. Started Jun 2013; status: completed.
02
Drugs
buprenorphine + naloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT01848054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01848054.